Psychedelic therapy

Mycotopia Therapies Inc. Begins Trading Under Symbol MYCO

Retrieved on: 
Tuesday, May 4, 2021
Health sciences, Drug discovery, Life sciences, Psychedelic therapy, Therapy

b'MIAMI, May 04, 2021 (GLOBE NEWSWIRE) -- Mycotopia Therapies Inc., (OTC Pink: MYCO), a company focused on psychedelic therapies, announced today its name and symbol change are complete.

Key Points: 
  • b'MIAMI, May 04, 2021 (GLOBE NEWSWIRE) -- Mycotopia Therapies Inc., (OTC Pink: MYCO), a company focused on psychedelic therapies, announced today its name and symbol change are complete.
  • With a primary focus of helping you heal and reclaim your life, Mycotopia Therapy endeavors to guide individuals through their journey of healing.
  • Psychedelic therapy is a holistic and spiritual approach providing healing and has shown successful treatment for many years.
  • All forward-looking statements included in this press release are made only as of the date of this press release.

Field Trip Health Ltd. Announces Opening of Psychedelic-Enhanced Therapy Center in Houston; Locations of Next 5 Field Trip Health Centers

Retrieved on: 
Tuesday, May 4, 2021
Health, Psychiatric diagnosis, Drug discovery, Psychedelic therapy, Psychiatry, Mental health, Management of depression, Major depressive disorder

The academic data matches closely with what we are seeing in our Field Trip Health centers -- that psychedelic-assisted therapy is a safe and effective treatment for depression, anxiety and other mental health challenges,\xe2\x80\x9d commented Dr. Ben Medrano, Field Trip\xe2\x80\x99s Senior Vice President and U.S. Medical Director.

Key Points: 
  • The academic data matches closely with what we are seeing in our Field Trip Health centers -- that psychedelic-assisted therapy is a safe and effective treatment for depression, anxiety and other mental health challenges,\xe2\x80\x9d commented Dr. Ben Medrano, Field Trip\xe2\x80\x99s Senior Vice President and U.S. Medical Director.
  • Each Field Trip Health center is designed to promote healing and provide people with a calming space before, during, and after treatment, and Houston is no different.
  • A great deal of consideration and thought also goes into making each Field Trip Health center suited for the community it serves.
  • Although the management of Field Trip believes that the assumptions underlying these statements are reasonable, they may prove to be incorrect.

Mydecine Reports Full Year 2020 Financial Results and Provides Business Update

Retrieved on: 
Monday, May 3, 2021
Drug discovery, Psychedelic therapy, Psychotherapy, Psychedelic drug, Medicine, Health sciences, Branches of biology

We focused on closing strategic acquisitions and partnerships, advancing our clinical trials and building our intellectual property portfolio to position Mydecine as a key player in the advancement of psychedelic-assisted psychotherapy,\xe2\x80\x9d stated Josh Bartch, CEO of Mydecine.

Key Points: 
  • We focused on closing strategic acquisitions and partnerships, advancing our clinical trials and building our intellectual property portfolio to position Mydecine as a key player in the advancement of psychedelic-assisted psychotherapy,\xe2\x80\x9d stated Josh Bartch, CEO of Mydecine.
  • The dial-in numbers for the conference call are 1-877-407-4018 (U.S. Toll Free) or 1-201-689-8471 (International).
  • Mydecine recognizes the responsibility associated with psychedelic-assisted therapy and will continue to position itself as a long-term leader across the spectrum of clinical trials, research, technology, and global supply.
  • Mydecine has also successfully completed multiple acquisitions since its inception.\n'

Lobe Sciences Enters into Joint Venture with Virtual Psychedelics Incorporated to Develop Multi-Sensory Pods for Clinical Psychedelic Use

Retrieved on: 
Tuesday, April 27, 2021
Articles, Academic disciplines, Mind, Abnormal psychology, Aftermath of war, Military personnel, Military sociology, Post-traumatic stress disorder, Psychiatric diagnosis, Psychedelic therapy, Mental health, Experience

Development of Krysalis(TM) Therapeutic Pod to Deliver Headset-free Virtual Experience with Biometric Monitoring

Key Points: 
  • Skip Rizzo, with respect to the joint design, development and commercialization of a new psychedelic/virtual experience ("VX") pod (the "KrysalisTM Pod").
  • Skip Rizzo, to be at the forefront of psychedelic research, development and treatment.
  • We believe this technology will be able to assist those suffering from depression, PTSD and other mental health issues.
  • Lobe will also issue 500,000 common shares to certain finders in connection with the transaction, at a deemed price of $0.20 per share.

Heroic Dose Event Explores Promise of Psychedelic Medicine for Veterans, Military & Servicemen and Women

Retrieved on: 
Thursday, April 8, 2021
Health sciences, Medicine, Psychiatry, Aftermath of war, Abnormal psychology, Military personnel, Post-traumatic stress disorder, Psychiatric diagnosis, Psychedelic therapy, Microdosing, Psychedelic drug

Toronto, Ontario--(Newsfile Corp. - April 8, 2021) - Microdose Psychedelic Insights , along with Entheon Biomedical Corp. , Bexson Biomedical , HavnLife and The Conscious Fund , present the Heroic Dose .

Key Points: 
  • Toronto, Ontario--(Newsfile Corp. - April 8, 2021) - Microdose Psychedelic Insights , along with Entheon Biomedical Corp. , Bexson Biomedical , HavnLife and The Conscious Fund , present the Heroic Dose .
  • The Heroic Dose will commence on 22nd April at 8:45 am EST.
  • This one-day virtual conference explores the use of psychedelic therapies for military veterans and first responders in an effort to combat the alarming rates of PTSD, substance abuse and suicide in this valuable yet underserved demographic.
  • This conference will feature some of the finest Navy SEAL and national security professionals, veterans and other servicemen and women, along with knowledgeable experts in psychedelic therapy, researchers, clinicians, companies, advocates.

MINDCURE Announces Additional Equity Investment in ATMA, The First Government Approved Psychedelic Journey Centers In Canada; MCUR President and CEO, Kelsey Ramsden Named to ATMA Board of Directors

Retrieved on: 
Thursday, April 8, 2021
Kelsey Ramsden, Psychedelic therapy, Atma, Kelsey, Corporate title, Business, Economy, Articles

Additionally, MINDCURE President and CEO Kelsey Ramsden will be joining the ATMA Board of Directors.

Key Points: 
  • Additionally, MINDCURE President and CEO Kelsey Ramsden will be joining the ATMA Board of Directors.
  • "We are extremely excited to strengthen our partnership with the team at ATMA through this investment.
  • ATMA's team is a true pioneer in the psychedelic therapy industry by growing a global network of group and retreat psychedelic therapy clinics," said Kelsey Ramsden, President and CEO, MINDCURE.
  • "We are thrilled today to welcome a visionary leader like Kelsey to our Board of Directors," said Vu Tran, Co-CEO of ATMA.

AIkido Granted Sublicense to Technology for Targeted Psilocybin Treatment of Neuro-Inflamed Tissue in Cancer Patients

Retrieved on: 
Wednesday, April 7, 2021
Psychoactive drugs, Branches of biology, Drug discovery, Psychedelic therapy, Psychedelic drug, Psilocybin, Medicine

The homing peptides covered by the sublicense can be used to facilitate the delivery of therapeutic agents to inflamed CNS tissue.

Key Points: 
  • The homing peptides covered by the sublicense can be used to facilitate the delivery of therapeutic agents to inflamed CNS tissue.
  • Anthony Hayes, CEO of AIkido Pharma, stated, "The novel homing peptides covered under this sublicense have the potential to allow the direct delivery of psilocybin to inflamed CNS tissue in cancer patients.
  • It complements our recently announced support of the psilocybin research for PTSD treatment at Mount Sinai Center for Psychedelic Psychotherapy and Trauma Research."
  • AIkido Pharma Inc. was initially formed in 1967 and is a biotechnology Company with a diverse portfolio of small-molecule anti-cancer therapeutics.

AIkido Pharma Sponsors Psychedelic Compound Research to Treat PTSD

Retrieved on: 
Monday, March 29, 2021
Psychiatry, Medical specialties, Post-traumatic stress disorder, Medicine, Aftermath of war, Adverse childhood experiences, Psychiatric diagnosis, Psychedelic therapy, Rachel Yehuda, Complex post-traumatic stress disorder

NEW YORK, March 29, 2021 /PRNewswire/ --AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that it is sponsoring psychedelic research at the Mount Sinai Center for Psychedelic Psychotherapy and Trauma Research (the "Center").

Key Points: 
  • NEW YORK, March 29, 2021 /PRNewswire/ --AIkido Pharma Inc. (Nasdaq: AIKI) ("AIkido" or the "Company") today announced that it is sponsoring psychedelic research at the Mount Sinai Center for Psychedelic Psychotherapy and Trauma Research (the "Center").
  • The Center examines the therapeutic potential of psychedelic compounds for post-traumatic stress disorder (PTSD) and other trauma-related symptoms.
  • Each year, over 8.6 million adults grapple with PTSD, and nearly ten percent of Americans will experience PTSD at some time in their lives.
  • Currently, no academic institution, other than the Center, is conducting research involving the administration of psychedelics inside the VA System.

Psychedelic Joint Venture Between Mycotopia Therapies and Natural MedTech Brings Research and Drug Development to Test Active Ingredient In Psychedelics

Retrieved on: 
Monday, March 22, 2021
Health sciences, Drug discovery, Health, Medicine, Hallucinations, Pharmaceutical industry, Clinical pharmacology, Psychedelic therapy, Psychotherapy, Clinical trial, Medtech, Psychedelic drug

PsyBioMed Australia will be a joint venture between Mycotopia Therapies and Melbourne, Victoria based psychedelic research and development company Natural MedTech.

Key Points: 
  • PsyBioMed Australia will be a joint venture between Mycotopia Therapies and Melbourne, Victoria based psychedelic research and development company Natural MedTech.
  • Medicallysupervised, legal access to evidence-based Psychedelic-Assisted Psychotherapy is becoming increasingly available through clinical trials for multiple conditions throughout Australia.
  • This research by the Australian government into whether psychedelic drugs are more effective than existing treatments sets the stage for large-scale clinical trials.
  • Natural MedTech conducts drug development, engages and supports clinical trials with the goal of advancing clinical application of psychedelics and other scheduled compounds of therapeutic relevance.

MINDCURE Names Tarik Lebbadi as Chief Operating Officer

Retrieved on: 
Monday, March 15, 2021
Given names, OTC Markets Group, Tariq, Psychedelic therapy, Branches of biology

VANCOUVER, BC, March 15, 2021 /PRNewswire/ -Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ("MINDCURE" or the "Company") a leader in advanced proprietary technology for psychedelic therapy, is pleased to announce that it has named Tarik Lebbadi as the Company's new Chief Operating Officer, effective immediately.

Key Points: 
  • VANCOUVER, BC, March 15, 2021 /PRNewswire/ -Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) ("MINDCURE" or the "Company") a leader in advanced proprietary technology for psychedelic therapy, is pleased to announce that it has named Tarik Lebbadi as the Company's new Chief Operating Officer, effective immediately.
  • "I am thrilled to welcome Tarik to MINDCURE today," said Kelsey Ramsden, President & CEO, MINDCURE.
  • Mr. Lebbadi began his career as a software engineer and has extensive operational experience with technology platforms.
  • "I could not be more excited to join the MINDCURE team today," said Tarik Lebbadi, COO, MINDCURE.